Abstracts Archive - Page 1539 of 2607 - ACR Meeting Abstracts

Abstract Number: 2276 • 2017 ACR/ARHP Annual Meeting
Etanercept (Enbrel®) Treatment Retention in the Sub-Population of Pediatric Patients from a Retrospective Cohort Study Using Canadian Claims-Level Data
Majed M M Khraishi¹, Brad Millson², John Woolcott³, Heather Jones⁴ and Lisa Marshall⁴, ¹Faculty of Medicine, Memorial University of Newfoundland, St John's, NF, Canada, ²Health Access and Outcomes, QuintilesIMS, Kanata, ON, Canada, ³Inflammation & Immunology Global Outcomes & Evidence,, Pfizer, Inflammation & Immunology Global Outcomes & Evidence, Collegeville, PA, ⁴Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA
Background/Purpose: Etanercept (ETN) was the first biologic approved for use in the treatment of patients with polyarticular-course juvenile idiopathic arthritis (JIA),1 and is now indicated…
Abstract Number: 2277 • 2017 ACR/ARHP Annual Meeting
Safety of Biologic Therapies for the Treatment of Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Juan José Bethencourt Baute¹, Carlos Sánchez-Piedra², Lorena Expósito Pérez¹, M. Victoria Hernández³, Javier Manero⁴, Rosa Rosello⁵, Fernando Sánchez-Alonso⁶, Dolores Ruiz-Montesinos⁷, Eva Perez Pampín⁸, Carlos Rodriguez-Lozano⁹, Cristina Campos Fernandez¹⁰, Cristina Fernández-Carballido¹¹, Raquel Martín-Domenech¹¹, Javier Del Pino-Montes¹², Mercedes Freire¹³, Federico Díaz-González¹⁴, Juan J. Gomez-Reino¹⁵ and Sagrario Bustabad¹⁶, ¹Servicio de Reumatología, Hospital Universitario de Canarias, Tenerife, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁴Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁵Hospital San Jorge, Huesca, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Hospital Virgen Macarena, Seville, Spain, ⁸Rheumatology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁹Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁰Rheumatology, Hospital Universitario de Valencia., Valencia, Spain, ¹¹Hospital General Universitario de Elda, Elda, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁴Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁵Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ¹⁶Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The treatment of JIA has been revolutionized by the use of…
Abstract Number: 2278 • 2017 ACR/ARHP Annual Meeting
Biologic Switching Among JIA Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa L. Mannion¹, Fenglong Xie², Daniel B. Horton³, Sarah Ringold⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic medications have allowed a significant proportion of JIA patients to achieve inactive disease. However, some patients will have ongoing moderate to high…
Abstract Number: 2279 • 2017 ACR/ARHP Annual Meeting
Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Ekaterina Alexeeva^1,2, Tatiana Dvoryakovskaya^1,2, Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova², Ksenia Isaeva², Olga Lomakina², Margarita Soloshenko² and Anna Karaseva², ¹Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ²Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The effectiveness of target use of biological medications depends on how personalized they are to fit patient’s individual parameters with juvenile idiopathic arthritis (JIA).…
Abstract Number: 2280 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova¹, Ksenia Isaeva¹, Olga Lomakina¹, Margarita Soloshenko¹ and Anna Karaseva¹, ¹Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The range of biological drugs currently used in JIA therapy includes not only anti-TNF but also other varieties. However, despite the high effectiveness and…
Abstract Number: 2281 • 2017 ACR/ARHP Annual Meeting
Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry
Sarah Ringold¹, Fenglong Xie², Daniel B. Horton³, Melissa L. Mannion⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Seattle Children's Hospital, Seattle, WA, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry began enrolling children with juvenile idiopathic arthritis (JIA) in July 2015. The large number of…
Abstract Number: 2282 • 2017 ACR/ARHP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Katherine Murphy⁹ and Yukiko Kimura⁶, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Parent Partner, San Francisco, CA
Background/Purpose: Despite the many available new and effective treatments for polyarticular JIA (P-JIA), there is significant variation in the timing of when biologic medications are…
Abstract Number: 2283 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy in Juvenile Idiopathic Arthritis: Addition of Lidocaine for Prevention of Injection Site Pain or Not? That Is the Question. a Comparison Study
Barbara Ostrov¹, Brandt Groh², Lisabeth V. Scalzi³, C. April Bingham², Natalya Gaffney², Meredith Buckley², Lisa Robbins² and Rosanne Ayala⁴, ¹Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ²Pediatrics, Penn State College of Medicine, Hershey, PA, ³Penn State Hershey Medical Center, Hershey, PA, ⁴Penn State College of Medicine, Hershey, PA
Background/Purpose: Up to 37% of patients prescribed adalimumab (AD) report significant injection-site pain (Registered Prescribing Information, 2016). For AD to be a stable pre-filled product,…
Abstract Number: 2284 • 2017 ACR/ARHP Annual Meeting
Use of Biological Therapies in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Carlos Sánchez-Piedra¹, Rosa Rosello², Javier Manero³, M. Victoria Hernández⁴, Fernando Sánchez-Alonso⁵, Eduardo Cuende⁶, Blanca García Magallon³, Ana M. Ortiz Garcia⁷, Cesar Diaz-Torné⁸, Mercedes Freire⁹, Paloma Vela¹⁰, Raúl Menor Almagro¹¹, Agueda Prior¹², Federico Díaz-González¹³, Juan J. Gomez-Reino¹⁴ and Sagrario Bustabad¹⁵, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital San Jorge, Huesca, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁶University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ⁷Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁸GEACSER, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁰Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ¹¹Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹²Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹³Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁴Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ¹⁵Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The advent of new biological drugs has changed the prognosis and…
Abstract Number: 2285 • 2017 ACR/ARHP Annual Meeting
Treatment of Adult Juvenile Idiopathic Arthritis Patients with Biologic Agents. Data from the National Registry
Katerina Jarosova¹, Lenka Szczukova², Zlatuse Kristkov³ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, ⁴Institute of Rheumatology, Prague 2, Czech Republic
Background/Purpose: To analyze the efficacy and safety of biologic agents in adult patients with juvenile idiopathic arthritis (JIA). Methods: ATTRA is a Czech national registry…
Abstract Number: 2286 • 2017 ACR/ARHP Annual Meeting
Determinants of Anti-Tumor Necrosis Factor Drug Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomes
Melissa Oliver¹, Julia F Simard², Dana Gerstbacher³, Tzielan Lee⁴ and Christy Sandborg⁵, ¹Pediatric Rheumatology, Stanford University, Department of Pediatric Rheumatology, Palo Alto, CA, ²Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA, ³Stanford University, Palo Alto, CA, ⁴Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁵Pediatric Rheumatology PTD, Stanford Medical Center, Palo Alto, CA
Background/Purpose: Patients with juvenile spondyloarthropathy (JSpA) have lower clinical remission rates, report higher pain scores, worse functioning and lower quality of life compared to other…
Abstract Number: 2287 • 2017 ACR/ARHP Annual Meeting
Biosimilar Use in Children and Young People with Juvenile Idiopathic Arthritis in a Real-World Setting in the United Kingdom
Diederik De Cock¹, Lianne Kearsley-Fleet¹, Eileen Baildam², Michael W. Beresford^3,4, Helen E. Foster⁵, Taunton R. Southwood⁶, Wendy Thomson^7,8 and Kimme L. Hyrich^1,8, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, United Kingdom, ⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁶School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Despite their increasing use in adults, there is little to no data available on the use of biosimilar drugs in children with JIA, despite…
Abstract Number: 2288 • 2017 ACR/ARHP Annual Meeting
Successful Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR)
Lea Höfel, Bruno Eppler, Elisabeth Schnöbel-Müller, Johannes Peter Haas and Boris Hügle, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of children with juvenile idiopathic arthritis (JIA). It frequently has to be discontinued due to intolerance…
Abstract Number: 2289 • 2017 ACR/ARHP Annual Meeting
Individualized Prediction of Early Remission on Medication in Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Kiem Oen³, Natalie J. Shiff⁴, Roberta Berard⁵, Roman Jurencak⁶, Adam Huber⁷, Kerstin Gerhold⁸, Susanne Benseler⁹, Ciarán M. Duffy¹⁰ and Lori Tucker¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Department of Pediatrics and Child Health University of Manitoba, Winnipeg, MB, Canada, ⁴University of Florida, Gainesville, FL, ⁵Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸Pediatrics, University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes cohort (ReACCh-Out) showed a 45% chance of attaining inactive disease within a year of…
Abstract Number: 2290 • 2017 ACR/ARHP Annual Meeting
Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Bin Huang¹, Esi Morgan², Chen Chen², Jinzhong Liu², Michelle Adams², Timothy Beukelman³, Hermine I. Brunner⁴ and Daniel J Lovell⁵, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati, OH
Background/Purpose: We compare the effectiveness of two approaches to treat Juvenile idiopathic arthritis (JIA): early combination of biologic and non-biologic disease modifying anti rheumatic drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].